title: Increased survival of free fat grafts and vascularization in rats with local delivery of fragmin/protamine microparticles containing FGF-2 (F/P MP-F).
abstract: We evaluated the effects of fragmin/protamine micro-particles (F/P MPs) containing FGF-2 (F/P MP-F) as carriers for the controlled release of FGF-2 for adipocyte-survival and capillary formation in inbred rats with subdivided free fat grafts. F/P MPs could immobilize FGF-2, thereafter gradually releasing the bound FGF-2. Inbred Fisher 344 rats weighing around 150 g were anesthetized and implanted with paste comprising harvested fat combined with F/P MP-F. The effect of F/P MP-F on the survival, granulation, and capillary formation in fat grafts was histologically compared with control grafts containing either FGF-2, F/P MPs or PBS. The control fat grafts became attached to tissues adjacent to the implantation site and were significantly resorbed after 30 days. In contrast, pink, soft, supple grafts were compressible and were little resorbed in the group given F/P FP MP-F at 30-120 days. Normal adipocytes were obviously decreased in the control groups with increased granulation tissues, whereas normal adipocytes with capillary formations were maintained in the F/P MP-F group. Thus, adding F/P MP-F to subdivided fat grafts helps to improve graft volume retention and survival in soft-tissue reconstruction through accelerating adipocyte-survival rates and angiogenesis.
authors.affiliation: Department of Plastic and Reconstructive Surgery, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan.
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Nakamura
authors.forename: Masayuki
authors.initials: M
authors.lastname: Ishihara
authors.forename: Megumi
authors.initials: M
authors.lastname: Takikawa
authors.forename: Kaoru
authors.initials: K
authors.lastname: Murakami
authors.forename: Satoko
authors.initials: S
authors.lastname: Kishimoto
authors.forename: Shingo
authors.initials: S
authors.lastname: Nakamura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yanagibayashi
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Mori
authors.forename: Masanori
authors.initials: M
authors.lastname: Fujita
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kubo
authors.forename: Naoto
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Tomoharu
authors.initials: T
authors.lastname: Kiyosawa
mesh_terms: D017667:Adipocytes / Q000166:cytology* / Q000637:transplantation; D000273:Adipose Tissue / Q000637:transplantation*; D000818:Animals; D000925:Anticoagulants; D002470:Cell Survival; D017985:Dalteparin / Q000627:therapeutic use; D004337:Drug Carriers / Q000737:chemistry*; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000494:pharmacology; D006085:Graft Survival / Q000187:drug effects*; D006494:Heparin Antagonists; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D011479:Protamines / Q000627:therapeutic use; D051381:Rats; D011916:Rats, Inbred F344
chemical_list: D000925:Anticoagulants; D004337:Drug Carriers; D006494:Heparin Antagonists; D011479:Protamines; D016222:Fibroblast Growth Factor 2; D017985:Dalteparin